Woman Dies After Using Weight-Loss Drug In U.K.'s First Case [Forbes]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Forbes
NurPhoto via Getty Images A 58-year-old nurse from Scotland has died after taking two doses of weight-loss medicine tirzepatide. Susan McGowan, 58, died from multiple organ failure, septic shock and pancreatitis, but her death certificate lists the Eli Lilly drug as a contributing factor, according to the BBC Her death is thought to be the first in the U.K. officially linked to the drug, which is also known as Mounjaro or Zepbound, depending on its use. McGowen took two low doses of the drug over around two weeks, according to the BBC . She had bought a prescription for the drug online A few days after her second dose, McGowen experienced sickness and severe stomach pain. She was treated by her colleagues at University Hospital Monklands in Airdrie, Lanarkshire, where she had worked for 30 years. Within days, McGowen developed serious kidney issues and went into a coma. Her other organs later failed. What Is Tirzepetide? Tirzepetide is one of several new “blockbuster”
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks [Yahoo! Finance]Yahoo! Finance
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeksPR Newswire
- Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA [Yahoo! Finance]Yahoo! Finance
- Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA [Yahoo! Finance Canada]Yahoo! Finance Canada
- Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics’ Founders to Company’s Scientific Advisory BoardBusiness Wire
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 11/8/24 - Form 144
- 11/8/24 - Form 4
- 11/5/24 - Form 4
- LLY's page on the SEC website